Evidence-based guideline for emetogenic risk classification, antiemetic regimen selection, and management of chemotherapy-induced nausea and vomiting.
A comprehensive, evidence-based clinical guideline for the prevention, assessment, and management of chemotherapy-induced nausea and vomiting (CINV). This document synthesizes recommendations from multiple international oncology professional societies, cooperative research groups, and expert consensus panels to provide a single, authoritative reference for clinicians involved in the care of patients receiving antineoplastic therapy.1
Nausea and vomiting remain among the most feared and distressing adverse effects of cytotoxic chemotherapy, and inadequate antiemetic prophylaxis significantly impairs patient quality of life, treatment adherence, nutritional status, and functional capacity. Without prophylaxis, 70% to 80% of patients receiving highly emetogenic chemotherapy (HEC) will experience significant nausea and vomiting.2 Advances in the understanding of the neuropharmacology of emesis — particularly the identification of the serotonin (5-HT3) and neurokinin-1 (NK1) receptor pathways — have led to the development of highly effective antiemetic regimens that can prevent emesis in the majority of patients when used according to evidence-based guidelines. The addition of olanzapine to standard three-drug regimens represents a major recent advance, with randomized trial data demonstrating superior nausea control in patients receiving HEC.3
Despite the availability of effective antiemetics, studies consistently demonstrate that 30% to 60% of patients receiving chemotherapy do not receive guideline-concordant antiemetic prophylaxis, and that adherence gaps are particularly prominent in the delayed phase (days 2 through 5 after chemotherapy) and in patients receiving moderately emetogenic regimens.4 This guideline aims to provide a practical, comprehensive reference to facilitate optimal antiemetic prescribing across all emetogenic risk categories.
This guideline covers the complete spectrum of CINV prevention and management:
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Emetogenic Classification and Risk Factors | Complete emetogenic classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal); types of CINV (acute, delayed, anticipatory, breakthrough, refractory); patient-related and treatment-related risk factors; pathophysiology of chemotherapy-induced emesis |
| Part 2 | Antiemetic Agents: Pharmacology, Dosing, and Adverse Effects | NK1 receptor antagonists; 5-HT3 receptor antagonists; corticosteroids; olanzapine; dopamine receptor antagonists; benzodiazepines; cannabinoids; mechanism of action, dosing, drug interactions, and side effect profiles for each agent class |
| Part 3 | Recommended Antiemetic Regimens and Special Populations | Guideline-recommended regimens by emetogenic risk level; multi-day chemotherapy protocols; oral chemotherapy-induced CINV; radiation-induced nausea and vomiting (RINV); breakthrough and refractory CINV management; pediatric, geriatric, and organ-impaired populations |
| Part 4 | Assessment Tools, Non-Pharmacological Interventions, and Implementation | CTCAE grading; MASCC Antiemesis Tool (MAT); patient assessment and monitoring; non-pharmacological interventions; guideline implementation and quality improvement; patient education |
Scope and Applicability: This guideline applies to all healthcare professionals involved in prescribing, administering, and monitoring antineoplastic therapy and its supportive care in adult and pediatric patients. This includes medical oncologists, hematologists, oncology nurse practitioners, physician assistants, clinical pharmacists, and oncology nurses across all care settings.
Limitations: No guideline can anticipate all clinical situations. This document is not intended to replace individual clinical judgment by qualified professionals. Local institutional protocols, formulary availability, patient-specific factors (including comorbidities, concomitant medications, and prior antiemetic response), and emerging evidence must always be considered in clinical decision-making.
This guideline synthesizes recommendations and evidence from: Hesketh PJ, Kris MG, Basch E, et al. “Antiemetics: ASCO Guideline Update.” Journal of Clinical Oncology, 38(24): 2782–2797, 2020. American Society of Clinical Oncology (ASCO). DOI: 10.1200/JCO.20.01296 | Roila F, Molassiotis A, Herrstedt J, et al. “2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.” Annals of Oncology, 27(suppl 5): v119–v133, 2016. Multinational Association of Supportive Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO). Updated 2023. | National Comprehensive Cancer Network (NCCN). “NCCN Clinical Practice Guidelines in Oncology: Antiemesis.” Version 1.2025. | Oncology Nursing Society (ONS). “Putting Evidence into Practice: Chemotherapy-Induced Nausea and Vomiting.” Updated 2024. | Razvi Y, Chan S, McFarlane T, et al. “ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients.” Supportive Care in Cancer, 27: 87–95, 2019. ↩︎
Hesketh PJ. “Chemotherapy-induced nausea and vomiting.” New England Journal of Medicine, 358(23): 2482–2494, 2008. DOI: 10.1056/NEJMra0706547 ↩︎
Navari RM, Qin R, Ruddy KJ, et al. “Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.” New England Journal of Medicine, 375(2): 134–142, 2016. DOI: 10.1056/NEJMoa1515725 ↩︎
Gilmore JW, Peacock NW, Gu A, et al. “Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.” Journal of Oncology Practice, 10(1): 68–74, 2014. DOI: 10.1200/JOP.2012.000816 ↩︎
Patient assessment and grading tools for CINV including CTCAE and MASCC Antiemesis Tool, evidence-based non-pharmacological interventions, guideline implementation strategies, quality improvement metrics, and patient education.
Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.
Comprehensive review of antiemetic drug classes used in CINV prophylaxis and treatment: NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, olanzapine, dopamine antagonists, benzodiazepines, and cannabinoids with complete dosing, pharmacokinetics, and adverse effect profiles.
Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.